- Insmed reported positive 12 month open label extension data for TPIP in pulmonary arterial hypertension.
- The study showed sustained improvements in six minute walk distance and NT proBNP, with no new safety signals reported.
- These results support Insmed’s plan to advance TPIP into a Phase 3 randomized, controlled trial.
For investors tracking Insmed, ticker NasdaqGS:INSM, the TPIP update adds a fresh data point to a stock that has moved sharply over multi year periods, with a very large 3 year return and a 346.9% return over 5 years. More recently, the share price sits at $108.32, up 10.0% over the past month but down 6.3% over the past week and down 38.8% year to date.
This new Phase 3 bound asset keeps the pipeline in focus for readers watching how Insmed’s R&D programs evolve over time. The upcoming randomized, controlled trial for TPIP will be an important next step. It could provide more clarity on how this candidate might fit into the pulmonary arterial hypertension treatment set if it progresses successfully through clinical testing.
Stay updated on the most important news stories for Insmed by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Insmed.
We've flagged 1 risk for Insmed. See which could impact your investment.
For Insmed, the 12 month TPIP open label extension readout speaks directly to the commercial potential of a once daily, inhaled prostanoid option in pulmonary arterial hypertension. The sustained gains in six minute walk distance, NT proBNP, functional class and risk score, together with no new safety signals at doses up to 1,280 µg, give the company a data package that can support both regulators and future payers as TPIP moves into Phase 3. Importantly, patients who originally received placebo and then switched to TPIP showed similar outcomes to those who continued on TPIP, which may help address questions about consistency of effect.
How This Fits Into The Insmed Narrative
- The TPIP data lines up with the existing narrative that Insmed is building a broader respiratory portfolio beyond Brinsupri and ARIKAYCE, with additional late stage assets that may support multi product revenue over time.
- At the same time, TPIP introduces another execution hurdle on top of Brinsupri launches and ARIKAYCE label work, which could stretch clinical, regulatory and commercial resources if timelines converge.
- The long term PAH opportunity for TPIP and its potential use in PH ILD, PPF and IPF are not fully reflected in the current storyline that is heavily focused on Brinsupri revenue targets.
Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Insmed to help decide what it's worth to you.
The Risks and Rewards Investors Should Consider
- ⚠️ The OLE study is not placebo controlled, so investors still need to see how TPIP performs in the Phase 3 PALM PAH randomized trial before relying on these efficacy trends.
- ⚠️ PAH is a competitive space with established prostacyclin based therapies from players such as Johnson & Johnson, Merck and United Therapeutics, so TPIP may face pricing and access pressure even if Phase 3 outcomes are favorable.
- 🎁 The 12 month data show consistent improvements across multiple clinically relevant endpoints, which may support a differentiated positioning for once daily TPIP if similar results are reproduced in the controlled trial.
- 🎁 The absence of new safety signals through 12 months and relatively low discontinuation rates could be an advantage when physicians and patients compare TPIP to existing multi dose or infusion based regimens.
What To Watch Going Forward
From here, investors following Insmed will want to track the progress of the Phase 3 PALM PAH trial, including timelines for full enrollment and any interim safety updates. Attention will also focus on how the company frames TPIP’s potential role versus current PAH standards of care and whether management begins to quantify the addressable market across PAH and related indications like PH ILD or IPF. Any commentary on regulator interactions, payer discussions or competitive responses in PAH from large players will also help clarify TPIP’s eventual commercial positioning within Insmed’s broader respiratory portfolio.
To ensure you're always in the loop on how the latest news impacts the investment narrative for Insmed, head to the community page for Insmed to never miss an update on the top community narratives.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com